Serum ferritin levels, socio-demographic factors and desferrioxamine therapy in multi-transfused thalassemia major patients at a government tertiary care hospital of Karachi, Pakistan

Haris Riaz1*, Talha Riaz2, Muhammad Ubaid Khan1, Sina Aziz3, Faizan Ullah1, Anis Rehman2, Qandeel Zafar4 and Abdul Nafey Kazi5

Abstract

Background: Beta thalassemia is the most frequent genetic disorder of haemoglobin synthesis in Pakistan. Recurrent transfusions lead to iron-overload manifested by increased serum Ferritin levels, for which chelation therapy is required.

Findings: The study was conducted in the Pediatric Emergency unit of Civil Hospital Karachi after ethical approval by the Institutional Review Board of Dow University of Health Sciences. Seventy nine cases of beta thalassemia major were included after a written consent. The care takers were interviewed for the socio-demographic variables and the use of Desferrioxamine therapy, after which a blood sample was drawn to assess the serum Ferritin level. SPSS 15.0 was employed for data entry and analysis.

Of the seventy-nine patients included in the study, 46 (58.2%) were males while 33 (41.8%) were females. The mean age was 10.8 (± 4.5) years with the dominant age group (46.2%) being 10 to 14 years. In 62 (78.8%) cases, the care taker education was below the tenth grade. The mean serum Ferritin level in our study were 4236.5 ng/ml and showed a directly proportional relationship with age. Desferrioxamine was used by patients in 46 (58.2%) cases with monthly house hold income significant factor to the use of therapy.

Conclusions: The mean serum Ferritin levels are approximately ten times higher than the normal recommended levels for normal individuals, with two-fifths of the patients not receiving iron chelation therapy at all. Use of iron chelation therapy and titrating the dose according to the need can significantly lower the iron load reducing the risk of iron-overload related complications leading to a better quality of life and improving survival in Pakistani beta thalassemia major patients.

Conflicts of Interest: None

Keywords: Beta thalassemia major, Ferritin, Desferrioxamine, Socio-demographic factors, Pakistan

Background

Beta thalassemia ranks first amongst the genetic disorders associated with haemoglobin synthesis in terms of prevalence and it is the result of an inherited defect in the synthesis of the beta chain of the adult haemoglobin. Consequently the erythropoiesis is defective and anemia is produced [1]. Considering the 5 to 7% carrier rate in Pakistan, the number of carriers is expected to approach 10 million [2]. This grades thalassemia as one of the most common inherited disorders in Pakistan [3]. Due to lack of appropriate documentation, precise data pertaining to the incidence and prevalence of the disease are lacking. However, different studies statistically estimate that the number of thalassemia major patients born each year is in the order of 4000 to 9000 [4,5]. Due to repeated blood transfusions, all thalassemic patients require Iron Chelation Therapy (ICT) in order
to reduce the increased iron load that if not eliminated properly can result in life threatening complications, including severe cardiac toxicity in the second decade of life, producing a significant decrease in the total life expectancy of these patients [6]. However, the practice of repeated parenteral ICT therapy imposes various economic burdens in those who cannot afford such a therapy. Oral chelators such as Deferasirox are much more expensive than the traditional ICT’s which makes access difficult for the majority of socio-economically underprivileged patients [7]. Desferoxamine (DFE), a parenteral drug used widely as ICT has been employed in the treatment of beta thalassemia for nearly four decades and has shown to be effective in reducing the hepatic and extra-hepatic adverse affects, particularly myocardial toxicity [8]. However, despite the protracted method of 8- to 10- hours of infusion at least five times a week, the patients suffering from beta thalassemia are often not able to achieve the desired threshold of Ferritin levels in their blood [9]. This study also highlighted the dismal situation of ICT having a negative impact on health related quality of life (HRQOL), and that in most of the cases compliance with ICT being suboptimal, signifying non-satisfactory provision of chelation therapy with respect to economic, clinical and quality of life related outcome.

The aim of the present study is to assess the socio-demographic factors, serum Ferritin levels and adherence to iron chelation therapy in multi-transfused Thalassemia major patients. The series is composed mainly of Thalassemics children and young patients.

Methodology
The present study is a continuation of the work on Thalassemia major patients and is carried out on the same patients in which the sero-prevalence of viral hepatitis and HIV was determined, published in the Tropical Dr. Journal [10]. However, the objectives are entirely different from the one published.

Study Design
This is a descriptive cross-sectional study, conducted from July to September 2009 at Karachi, Pakistan’s largest city both in terms of area and inhabitants.

Setting
This study was conducted at Civil Hospital Karachi, one of the largest government tertiary care hospitals of Karachi. The hospital has a Paediatric Emergency Unit (PEU) specialized for the treatment of children presenting with acute medical problems. Patients with transfusion dependent Thalassemia (Thalassemia major) also present to the PEU for the routine follow up and transfusions. The fee structure of the hospital is such that patients with lower socioeconomic strata of the city and those referred from other centres are treated.

Participants
Diagnosed cases of Thalassemia major that had undergone at least ten transfusions were included after obtaining a written consent from their care takers. Those who did not give consent or had lesser number of transfusions were excluded from the study.

Study
The sampling technique was non-probability purposive sampling. The care takers of the Thalassemia major patients providing consent were interviewed by the students of Dow Medical College (DMC) through a well structured questionnaire prepared after literature search and modified in terms of questionnaire clarity. The first section comprised of Socio- Demographic variables. These included age, gender, area of residency, status of house (whether owned or at rent), monthly house-hold income and education of the parents. The second part was pertaining to history of vaccination for Hepatitis B and blood group. At the completion of interview a blood sample was obtained by venepuncture from the patient for serological analysis of serum Ferritin levels.

Ethical Approval
The ethical approval for the study was obtained from the Ethical Review Board (ERB) of the Dow University of Health Sciences (DUHS).

Results
A total of 79 patients were enrolled in the study duration. The mean age was 10.8 ± 4.5 years. As shown in Table 1, 46 (58.2%) were males where as the rest i.e. 33 (41.8%) were females. Half of the patients were between ages 9 and 15 years.

Blood group “O” was found to be the predominant. The results highlight the education status of the patients showing that 78.8% of the care takers of the patients had education less than the Matric (39.4% stating that they “never went to school”, and an equal number responding that they left the school during the primary education). Most of the patients belonged to a poor socio-economic background reflected from the monthly house hold income with all the care takers having income below 20,000 Pakistani Rupees PKR (Approximately 245 US dollars) per month. The preponderance (36.4%) lies between 5000-10,000 PKR (61 US dollars - 122 US dollars) per month. Approximately three fourths (75.8%) stated that they owned a house. The vaccination history revealed that less than half (45.5%) care takers stated that they vaccinated their children for Hepatitis B.
while 12.1% not even knew whether they have carried out the procedure or not.

The mean serum Ferritin levels were found to be 4236.5 (± 2378.3) ng/ml. The values in males were similar (4075.2 ± 2440.7) ng/ml compared to females (4461 ± 2306.6) ng/ml. The figure was less than 1000 ng/ml in just 2 cases, whereas the values were between two to three thousand ng/ml in 19 cases. Figure 1 displays the serum Ferritin ranges and the number of patients who fall within a specified range. 11 cases had serum Ferritin values exceeding 7000 ng/ml. The values increased progressively with age above 9 years as suggested in Figure 2.

Desferrioxamine therapy was used by three fifth of the patients. As expected, serum Ferritin values were much lower (3319.6 ± 1925.8) ng/ml in the group who received the therapy compared to those who did not use the medication (5514.8 ± 2383.0) ng/ml. Monthly household income was associated with use of Desferrioxamine therapy, with just one third of patients below income of 3000 Rupees per month taking the medication compared to over two thirds above that income.

### Discussion
Iron overload is an unavoidable complication suffered by thalassemia major patients as a consequence of excessive number of blood transfusions. It is so common that it has been referred to a “second disease” during treatment of first [11]. Serum Ferritin is an easy and inexpensive indirect measurement of iron burden, however, a single measure may not provide reliable indication of iron levels. The new non-invasive methods of measuring iron storage in the body such as MRI or SQUID have greater sensitivity, but they have limited use in developing countries such as Pakistan because of cost and complexity. As excessive iron can lead to organ complications, chelation therapy is employed to lower its levels. Borgna-Pignatti et al reported that a lower Ferritin concentration predicted longer survival, and reduced risk of various complications [12]. Many studies concluded that cirrhosis of liver is associated with increase in serum Ferritin level [13-16].

Patients with lower socio-economic strata visit the government tertiary care hospitals as depicted in our
results. All the patient’s care takers had a monthly income below 20,000 rupees per month. Considering the average 500 mg vial price of desferrioxamine to be 150-180 rupees (Approximately 5000 rupees per month), it’s exceedingly difficult for the care takers to cope with the therapy. These prices do not include infusion devices, the cost of which is covered by the hospital through governmental funding. Table 2 depicts the effect of gender and monthly household income on the use of Desferrioxamine therapy.

When not provided with desferrioxamine therapy the patients suffer grave consequences of iron overload, the spectrum of which lies from generalized weakness, weight loss, joint pain, abdominal pain to critical illness such as cirrhosis, hepatoma, diabetes, cardiomyopathy, arthritis, arthropathy, hypopituitarism with hypogonadism and death [17]. The organ most sensitive to chronic iron overload is heart. Chronic iron overload in liver increases chances of cirrhosis and hepatic carcinoma, hepatoma. The death occurs mostly due to liver disease, hepatocellular carcinoma, diabetes or cardiomyopathy [18]. However, T2 weighted Magnetic Resonance Imaging (MRI) studies show that Desferrioxamine is not as cardio-protective as the oral chelator deferiprone as oral deferiprone is more effective than desferrioxamine in removal of myocardial iron [19]. Furthermore, Desferrioxamine therapy is associated with adverse effects and demands associated with administration regimen rendering the compliance sub-optimal. A combination regimen of Desferrioxamine with Deferiprone is shown to be the most rapid way of reducing iron-overload in both liver and heart.

The mean serum Ferritin level in our study was 4236.5 ng/ml, which is markedly higher when compared to normal serum Ferritin levels in children in which the mean serum Ferritin level is considered to be in range of 12-122 ng/ml [20]. The values in our study are higher compared with similar regional and international studies. A study conducted in Islamabad, the federal capital of our country showed the mean serum Ferritin level in patients of beta thalassemia was 3390 ng/ml [21]. Cunningham et al in 2004 reported mean serum Ferritin levels in beta thalassemia patients of North America to be 1696 ng/ml [22]. The difference is largely attributable to the difference in the standards of healthcare between the 2 regions. For instance, the dosage was not adjusted with weight in our group of patients, which could contribute to high Ferritin levels. However, Choudhry VP et al in India reported mean serum Ferritin levels to be 6723 ng/ml [23], even higher than in our study.

Age and chelation therapy are significantly linked with Ferritin levels in our study. This is depicted in the graph (Figure 2) below, which outlines that there is a directly proportional relationship between age in years and the serum Ferritin levels. Approximately four-fifths of the patients in our study had serum Ferritin values exceeding 2000 ng/ml, which is almost ten times higher than the upper limit of normal. As expected, serum Ferritin values were much lower (3319.6 ± 1925.8) in the group who received the therapy compared to those who did not use the medication (5514.8 ± 2383.0). Monthly household income was associated with use of Desferrioxamine therapy, with just one third of patients below income of 3000 Rupees per month taking the medication compared to over two thirds above that income. Interestingly, female gender was associated with increased use of Desferrioxamine therapy.

The importance of chelation therapy can be appreciated from the fact that levels of Ferritin are inversely linked to the survival in Thalassemia major patients. A study reported that the 15 year cardiac disease free survival in patients on iron chelation therapy with Ferritin levels below 2500 ng/ml was 91% compared to under 20% with levels in excess of this value [24].

| Variable                  | Total Number | Percentage |
|---------------------------|--------------|------------|
| Gender                    |              |            |
| Male                      | 46           |            |
| On DFE                    | 24           | 52.2       |
| Without DFE               | 22           | 47.8       |
| Females                   | 33           |            |
| On DFE                    | 22           | 66.6       |
| Without DFE               | 11           | 33.3       |
| House hold income (Rs.)   |              |            |
| Less than 3000            | 20           | 25.3       |
| On DFE                    | 8            | 40.0       |
| Without DFE               | 12           | 60.0       |
| 3000-5000                 | 35           | 44.3       |
| On DFE                    | 23           | 65.7       |
| Without DFE               | 12           | 34.3       |
| 5000-10000                | 22           | 27.8       |
| On DFE                    | 14           | 63.6       |
| Without DFE               | 8            | 36.4       |
| 10000-20000               | 2            | 2.5        |
| On DFE                    | 1            | 50.0       |
| Without DFE               | 1            | 50.0       |

DFE = Desferrioxamine

Table 2 Effect of Gender and House Hold Income on Desferrioxamine Use

http://www.biomedcentral.com/1756-0500/4/287
Limitations
The height and weight (and consequently the body mass index) of the patients was not obtained. The dose and frequency of Desferrioxamine infusions is not ascertained and is also a limitation.

Conclusions
The problems of poverty, low education level and inadequate provision of health care are the main stumbling blocks in effective treatment of thalassemic patients of iron overload, the complications of which are the main cause of morbidity and mortality in thalassemia major.

Recommendations
Use of Deferiprone, routine measurements of serum Ferritin levels, adherence to guidelines, awareness amongst the public for prevention of the disease and antenatal diagnosis are some of the methods which can decrease the sufferings of not only the patients, but also of their families.

Acknowledgements
The authors are grateful to Areeba Ejaz and Muhammad Hasan, House Officers, Civil Hospital Karachi, Pakistan for their help in data collection. Financial Support
None

Author details
1House officer, Civil Hospital Karachi, Pakistan. 2Medical graduates, Civil Hospital Karachi, Pakistan. 3Associate Professor, Department of Paediatrics, Dow University of Health Sciences, Karachi, Pakistan. 4Electives students, Department of Paediatrics, Civil Hospital Karachi, student of King Dow University of Health Sciences, Karachi, Pakistan. 5Medical student, Dow Medical College, Karachi, Pakistan.

Authors' contributions
HR and TR conceived the study. HR, MUK and TR wrote the manuscript under supervision of SA. FU, QZ, ANK and AR contributed in the study design and data analysis. All the authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Received: 11 July 2011 Accepted: 11 August 2011 Published: 11 August 2011

References
1. Fairweather DV, Modell B, Berdoukas V, Alter BP, Nathan DG, Loukopoulos D, Wood W, Clegg JH, Weatherall DJ: Antenatal diagnosis of thalassemia major. Br Med J 1978, 1:350-353.
2. Lodhi Y: Economics of thalassemia management in Pakistan. In Thalassemia Awareness Week Edited by: Ahmed S; Friends of Thalassemia 2003.
3. Khatib B, Moatser T, Shaghil AM, Haroon S, Kakepoto GN: Genetic diversity of beta-thalassemia mutations in Pakistani population. J Pak Med Assoc 2000, 50:293-96.
4. Ahmed S, Petrous M, Saleem M: Molecular genetics of b-thalassemia in Pakistan. A basis for prenatal diagnosis. Br J Haematol 1996, 94:476-82.
5. Arif F, Fayyaz I, Hamid A: Awareness among parents of children with thalassemia major. J Pak Med Assoc 2008, 58:621-624.
6. Porter JB: A risk-benefit assessment of iron-chelation therapy. Drug Saf 1997, 17:407-21.
7. Vprakasit V, Lee-Lee C, Chong QT, Lin KH, Khuhapraya A: Iron chelation therapy in the management of thalassemia: the Asian perspectives. Int J Hematol 2009, 90:435-45.
8. Porter JB: Optimizing iron chelation strategies in beta-thalassaemia major. Blood Rev 2009, 23:53-7.
9. Payne KA, Roafal D, Baladi JF, Vala M, Abetz L, Desrosiers MP, Lordan N, Ishak K, Proskorovsky I: Iron chelation therapy: clinical effectiveness, economic burden and quality of life in patients with iron overload. Adv Ther 2008, 25:725-42.
10. Riaz H, Riaz T, Ullah F, Aziz S, Khan MIJ, Penaiz R, Ejez A, Hasan M, Moiz F, Naqvi SA: Assessment of the seroprevalence of viral hepatitis B, viral hepatitis C and HIV in multitransfused thalassemia major patients in Karachi, Pakistan. Trop Doct 2011, 41:23-25.
11. Cohen AR: Management of iron overload in the pediatric patient. Hematol Oncol Clin North Am 1987, 1:521-544.
12. Borgna-Pignotti C, Rugotto S, De Stefano: Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004, 89:1187-93.
13. Mary AK, Jonathan AS, Lan GC, Suzy VT, Frank MT: Ferritin for the clinician. Blood Rev 2009, 23:95-104.
14. Jill W, Vincent JF, Terri G, Ernest B: Screening for hemochromatosis by measuring Ferritin levels: a more effective approach. Blood 2008, 111:3373-3376.
15. Beaton M, Guyader D, Deugnier Y, Moisand R, Chakrabarti S, Adams P: Noninvasive prediction of cirrhosis in C282Y-linked hemochromatosis. Hepatology 2002, 36(3):673-678.
16. Fletcher LM, Dixon JL, Purdie DM, Powell LW, Crawford DH: Excess alcohol greatly increases the prevalence of cirrhosis in hereditary hemochromatosis. Gastroenterol 2002, 122:281-289.
17. Witte DL, Crosby WH, Edwards CQ, Fairbanks V, Vitros FA: Practice Guideline Development Task Force of the College of American Pathologists. Hereditary hemochromatosis. Clin Chim Acta 1996, 245:139-200.
18. Cogwell ME, McDonnell SM, Khoury MJ, Franks AL, Burke W, Brittenham GM: Iron overload, Public Health, and Genetics: Evaluating the Evidence for Hemochromatosis Screening. Ann Intern Med 1998, 129:971-979.
19. Anderson L, Wonke B, Prescott E, Holden S, Walker JM, Pen nell DJ: Comparison of effects of oral deferasirox and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassemia. The Lancet 2002, 360:516-520.
20. Hows J, Husseen S, Hoffbrand AV, Wickramasinghe SN: Red Cell indices and serum Ferritin level in children. J Clin Path 1977, 30:181-183.
21. Iram N, Hassan K, Younas M, Amanat S: Ferritin levels in patients of Beta Thalassemia major. Int J Pathol 2004, 2:71-74.
22. Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR: Iron overload, Public Health, and Genetics: Evaluating the Evidence for Hemochromatosis Screening. Ann Intern Med 1998, 129:971-979.
23. Choudhry VP, Pati HP, Savina A, Malaviya AN: Deferiprone, efficacy and safety. Indian J Pediatr 71(3):213-216.
24. Olivieri NF, Nathan DG, MacMillan JH, et al: Survival in medically treated patients with homozygous beta thalassemia. N Engl J Med 1994, 331:574-578.